Result of AGM and Directorate Changes
Updated : 14:54
29 July 2020
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Result of AGM and Directorate Changes
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were passed on a poll. The results of the proxy voting for the AGM are set out below:
Resolution | Total votes For1 | % of votes cast2 | Total Votes Against | % of votes cast2 | Votes Withheld3 |
1. To receive the audited financial statements and the Auditor's and Directors' reports for the year ended 31st December 2019. | 172,734,768 | 99.95 | 90,000 | 0.05 | 3,013 |
2. To re-appoint Michael Bradfield as a Director of the Company. | 172,734,286 | 99.95 | 93,330 | 0.05 | 165 |
3. To re-appoint Hans von Celsing as a Director of the Company. | 172,734,286 | 99.95 | 93,330 | 0.05 | 165 |
4. To re-appoint Prof. Steve Myers as a Director of the Company. | 172,824,286 | 99.99 | 830 | 0.01 | 2,665 |
5. To re-appoint Dr Nick Plowman as a Director of the Company. | 172,824,286 | 99.99 | 830 | 0.01 | 2,665 |
6. To re-appoint Nicolas Serandour as a Director of the Company. | 172,824,286 | 99.99 | 830 | 0.01 | 2,665 |
7. To re-appoint Dr Michael Sinclair as a Director of the Company. | 172,826,786 | 99.99 | 995 | 0.01 | 0 |
8. To re-appoint Dr Enrico Vanni as a Director of the Company. | 172,736,786 | 99.95 | 90,830 | 0.05 | 165 |
9. To re-appoint Renhua Zhang as a Director of the Company. | 172,823,286 | 99.99 | 1,830 | 0.01 | 2,665 |
10. To re-appoint RPG Crouch Chapman LLP as Auditors of the Company to hold office until the conclusion of the next AGM at which accounts are laid before the Company | 172,826,951 | 100.00 | 0 | 0.00 | 830 |
11. To authorise the Directors to determine the remuneration of the Auditors. | 172,823,451 | 99.90 | 3,500 | 0.01 | 830 |
12. Authority to allot shares | 172,822,517 | 99.99 | 5,264 | 0.01 | 0 |
13. Authority to disapply pre-emption rights | 172,703,050 | 99.93 | 124,566 | 0.07 | 165 |
Notes
1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution
Directorate Changes
As announced on 8 June 2020, Mr Gabriel Urwitz, Mr Peter Sjöstrand, Mr Chunlin "Allen" Han and Dr Yuelong Huang (all Non-Executive Directors of the Company) did not seek re-election at the Company's AGM. Accordingly, these directors have now stepped down from the Board with immediate effect and consequently the size of the Board has decreased from 12 to 8 people.
- ENDS -
Advanced Oncotherapy plc | |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO | |
Allenby Capital Limited (Nomad & Broker) | |
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales & Broking) | Tel: +44 (0) 20 3328 5656 |
FTI Consulting (Financial PR & IR) | |
Simon Conway / Rob Winder | Tel: +44 (0) 20 3727 1000 |
Notes for Editors
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.